Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21187798 | 1.00 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL21952754 | 0.94 | KMT2A (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL21952847 | 0.94 | KMT2A (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23843980 | 0.88 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL29895514 | 0.88 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23843996 | 0.88 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL29895510 | 0.88 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19726539 | 0.88 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL29831011 | 0.85 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19209721 | 0.85 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4644394-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4106876-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250002513-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| CN-118598916-A | Antiviral compounds | 吉利德科学公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-115135383-B | Antiviral compounds | 吉利德科学公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-4106876-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-115135383-A | Antiviral compounds | 吉利德科学公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| CN-107709288-A | Phosphamide derivative and preparation method and application thereof | 四川海思科制药有限公司 | 2018-02-16 | — | — | CN | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | CA1 4883/4885CA2 4733/4885CA7 4448/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | CA1 4717/4885CA2 2768/4885CA7 3777/4885 |
| US-20250002513-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | CA1 4883/4885CA2 4733/4885CA7 4448/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | CA1 4883/4885CA2 4733/4885CA7 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.